Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1201 - 1300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1201 | 24973609 |
US |
46 | 1 |
Accidental exposure to product, Device dispensing error, Incorrect dose administered by device, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 1202 | 24974242 |
US |
82 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 1203 | 24974289 |
US |
2 | |
Accidental exposure to product, Toxicity to various agents, Renal failure, Hypotension, |
||||
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE, WARFARIN, |
||||
| 1204 | 24974305 |
US |
36 | 2 |
Accidental exposure to product, Headache, Device difficult to use, Wrong technique in product usage process, Drug dose omission by device, Injection site pain, Inappropriate schedule of product administration, |
||||
ERENUMAB-AOOE, |
||||
| 1205 | 24974329 |
US |
1 | |
Device defective, Product dose omission issue, Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 1206 | 24975124 |
CA |
71 | 2 |
Lower respiratory tract infection, Accidental exposure to product, Blood pressure fluctuation, Infusion site discharge, Infusion site reaction, Incorrect dose administered, Product dispensing error, Blood potassium increased, Wrong technique in product usage process, Device alarm issue, Skin infection, Incorrect drug administration rate, Blood pressure increased, Infusion site swelling, Infusion site pain, Infusion site erythema, Infusion site pruritus, |
||||
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, OXYBUTYNIN, VANCOMYCIN HYDROCHLORIDE, OXYBUTYNIN, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, |
||||
| 1207 | 24975131 |
US |
||
Syringe issue, Needle issue, Accidental exposure to product, Device issue, |
||||
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT), |
||||
| 1208 | 24975699 |
US |
70 | 1 |
Food poisoning, Device difficult to use, Accidental exposure to product, Drug dose omission by device, Product administration error, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 1209 | 24975770 |
US |
59 | 1 |
Drug delivery system malfunction, Wrong technique in product usage process, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 1210 | 24975771 |
US |
||
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1211 | 24975922 |
US |
74 | 1 |
Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Product communication issue, Drug dose omission by device, Asthenia, Malaise, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1212 | 24975995 |
US |
35 | 2 |
Needle issue, Product dose omission issue, Anaphylactic reaction, Scratch, Accidental exposure to product, Hypersensitivity, Device defective, Headache, Urticaria, |
||||
OMALIZUMAB, OMALIZUMAB, DOXEPIN, DOXEPIN HYDROCHLORIDE, PYRIDOSTIGMINE BROMIDE, HYDROXYZINE, IMATINIB MESYLATE, MONTELUKAST SODIUM, MONTELUKAST SODIUM, NAPROXEN, NAPROXEN SODIUM, NAPROXEN, NAPROXEN SODIUM, |
||||
| 1213 | 24976062 |
SE |
||
Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 1214 | 24976176 |
US |
1 | |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product complaint, |
||||
FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 1215 | 24976390 |
CA |
55 | 1 |
Product leakage, Accidental exposure to product, Inappropriate schedule of product administration, Device defective, |
||||
GOLIMUMAB, |
||||
| 1216 | 24976784 |
US |
49 | |
Accidental exposure to product, Device defective, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 1217 | 24977048 |
GB |
6 | 1 |
Injection site haemorrhage, Device use issue, Device leakage, Incorrect dose administered by device, Accidental exposure to product, Exposure via skin contact, Off label use, Drug dose omission by device, Product solubility abnormal, Device difficult to use, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 1218 | 24977138 |
US |
43 | 2 |
Product dose omission issue, Accidental exposure to product, Device defective, |
||||
GUSELKUMAB, |
||||
| 1219 | 24977487 |
US |
81 | 2 |
Lacrimation increased, Vision blurred, Exposure via skin contact, Accidental exposure to product, |
||||
TOBRAMYCIN AND DEXAMETHASONE, |
||||
| 1220 | 24977641 |
US |
1 | |
Accidental exposure to product, Device issue, Device delivery system issue, Device leakage, Exposure via skin contact, |
||||
SECUKINUMAB, |
||||
| 1221 | 24978225 |
US |
13 | 1 |
Therapeutic product effect incomplete, Wrong technique in device usage process, Accidental exposure to product, Injection site discharge, Device leakage, Exposure via skin contact, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 1222 | 24978233 |
AU |
18 | 2 |
Device mechanical issue, Device difficult to use, Injection site pain, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, |
||||
| 1223 | 24978319 |
US |
2 | |
Device issue, Accidental exposure to product, Incorrect dose administered by device, |
||||
SECUKINUMAB, |
||||
| 1224 | 24973097 |
US |
1 | |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1225 | 24973232 |
US |
49 | 2 |
Accidental exposure to product, Device issue, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 1226 | 24973256 |
US |
61 | 1 |
Injection site pain, Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 1227 | 24972806 |
US |
63 | 1 |
Disability, Device difficult to use, Accidental exposure to product, Occupational exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 1228 | 24972813 |
US |
63 | 2 |
Product dose omission issue, Device issue, Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 1229 | 24972880 |
US |
2 | |
Off label use, Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1230 | 24972976 |
US |
2 | |
Accidental exposure to product, Pruritus, Urticaria, |
||||
IOPAMIDOL, |
||||
| 1231 | 24967757 |
US |
72 | 1 |
Device difficult to use, Drug dose omission by device, Accidental exposure to product, Wrong technique in product usage process, Rhinorrhoea, Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, SEMAGLUTIDE, |
||||
| 1232 | 24967846 |
US |
||
Adverse event, Accidental exposure to product, |
||||
| 1233 | 24967944 |
US |
79 | 2 |
Accidental exposure to product, Injection site haemorrhage, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1234 | 24967995 |
US |
52 | 2 |
Injection site pain, Exposure via skin contact, Injection site swelling, Pruritus, Insomnia, Device use error, Accidental exposure to product, Extra dose administered, |
||||
BELIMUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 1235 | 24968271 |
US |
67 | 2 |
Injection site haematoma, Injection site bruising, Accidental exposure to product, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 1236 | 24968782 |
US |
1 | |
Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 1237 | 24968919 |
US |
41 | 2 |
Needle issue, Product dose omission issue, Underdose, Product dispensing issue, Drug delivery system malfunction, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 1238 | 24969019 |
US |
16 | 1 |
Accidental exposure to product, Product use issue, |
||||
IBUPROFEN, |
||||
| 1239 | 24969965 |
US |
44 | 2 |
Product dose omission issue, Needle issue, Accidental exposure to product, Device deployment issue, Device leakage, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 1240 | 24970040 |
US |
96 | 1 |
Acute myocardial infarction, Post procedural cellulitis, Weight decreased, Device difficult to use, Drug dose omission by device, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 1241 | 24970267 |
US |
83 | 1 |
Device difficult to use, Drug dose omission by device, Accidental exposure to product, Lack of injection site rotation, Incorrect dose administered by device, Injection site mass, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1242 | 24970347 |
BE |
31 | 2 |
Posterior reversible encephalopathy syndrome, Ventricular fibrillation, Tachycardia, Hypertension, Accidental overdose, Accidental exposure to product, Cyanosis, Cardiomyopathy, |
||||
EPINEPHRINE, ADRENALINUM, DEXMEDETOMIDINE, PROPOFOL, ROCURONIUM, ROCURONIUM BROMIDE, TRANEXAMIC ACID, CEFAZOLIN SODIUM, |
||||
| 1243 | 24970971 |
US |
67 | 1 |
Surgery, Post procedural infection, Influenza, Urinary tract infection, Viral infection, Device difficult to use, Accidental exposure to product, Drug dose omission by device, Off label use, |
||||
EVOLOCUMAB, OXYGEN, 0XYGEN, |
||||
| 1244 | 24970979 |
US |
67 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 1245 | 24971108 |
US |
2 | |
Accidental exposure to product, Needle issue, Syringe issue, Device leakage, |
||||
CANAKINUMAB, |
||||
| 1246 | 24971298 |
US |
50 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 1247 | 24971326 |
US |
1 | |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1248 | 24971505 |
US |
11 | 2 |
Needle issue, Device leakage, Accidental exposure to product, Exposure via skin contact, Device delivery system issue, Incorrect dose administered by device, |
||||
SOMATROPIN, |
||||
| 1249 | 24972116 |
US |
1 | |
Device deployment issue, Accidental exposure to product, Drug dose omission by device, Exposure via skin contact, Device delivery system issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 1250 | 24972232 |
US |
77 | 1 |
Injection site haemorrhage, Device difficult to use, Drug dose omission by device, Accidental exposure to product, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1251 | 24962776 |
US |
40 | 2 |
Injection site pain, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1252 | 24962812 |
US |
54 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1253 | 24962816 |
US |
41 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1254 | 24962823 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1255 | 24962829 |
US |
86 | 2 |
Knee operation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1256 | 24962846 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1257 | 24962877 |
US |
53 | 2 |
Dermatitis atopic, Stress, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1258 | 24962933 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1259 | 24962941 |
US |
18 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1260 | 24962982 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1261 | 24963001 |
US |
41 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1262 | 24963009 |
US |
73 | 1 |
Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1263 | 24963212 |
US |
74 | 2 |
Underdose, Pain, Ill-defined disorder, Haemorrhage, Accidental exposure to product, Drug delivery system malfunction, Cortisol abnormal, |
||||
TOCILIZUMAB, TOCILIZUMAB, PREDNISONE, PREDNISONE, LOSARTAN, ROSUVASTATIN, LEVOTHYROXINE SODIUM, |
||||
| 1264 | 24963250 |
US |
||
Haemorrhage, Accidental exposure to product, Product delivery mechanism issue, |
||||
CANTHARIDIN, |
||||
| 1265 | 24963537 |
US |
45 | 2 |
Weight abnormal, Device difficult to use, Drug dose omission by device, Accidental exposure to product, Wrong technique in product usage process, |
||||
ERENUMAB-AOOE, |
||||
| 1266 | 24964062 |
US |
2 | |
Incorrect dose administered by device, Accidental exposure to product, |
||||
SECUKINUMAB, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, |
||||
| 1267 | 24964194 |
US |
81 | 2 |
Dental operation, Pulmonary embolism, Blood cholesterol increased, Device difficult to use, Accidental exposure to product, Product communication issue, Blood glucose increased, |
||||
EVOLOCUMAB, |
||||
| 1268 | 24964372 |
US |
53 | 2 |
Product dose omission issue, Device issue, Accidental exposure to product, Pain, |
||||
GUSELKUMAB, |
||||
| 1269 | 24964655 |
US |
2 | |
Drug dose omission by device, Device mechanical issue, Device delivery system issue, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 1270 | 24965064 |
US |
||
Occupational exposure to product, Accidental exposure to product, Intercepted product preparation error, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 1271 | 24965163 |
US |
1 | |
Incorrect dose administered by device, Accidental exposure to product, Device issue, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 1272 | 24965269 |
US |
56 | 2 |
Injection site pain, Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, Product dose omission issue, |
||||
ERENUMAB-AOOE, METOPROLOL TARTRATE, METOPROLOL, SEMAGLUTIDE, UBROGEPANT, SERTRALINE HYDROCHLORIDE, |
||||
| 1273 | 24965530 |
AU |
36 | 2 |
Lower respiratory tract infection, Illness, COVID-19, Device malfunction, Incorrect dose administered by device, Accidental exposure to product, Inappropriate schedule of product administration, |
||||
OFATUMUMAB, OFATUMUMAB, OFATUMUMAB, OFATUMUMAB, OFATUMUMAB, |
||||
| 1274 | 24966262 |
US |
1 | |
Accidental exposure to product, Device deployment issue, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1275 | 24966351 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Circumstance or information capable of leading to medication error, Drug ineffective, |
||||
| 1276 | 24966397 |
US |
1 | |
Accidental exposure to product, Incorrect dose administered, Device leakage, Product knowledge deficit, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 1277 | 24966518 |
US |
67 | 2 |
Bronchiectasis, Condition aggravated, Pulmonary congestion, Dyspnoea, Sleep disorder due to a general medical condition, Fatigue, Rosacea, Flushing, Asthma, Incorrect dose administered, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, PREDNISONE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, MONTELUKAST, PREDNISONE, |
||||
| 1278 | 24966536 |
US |
2 | |
Accidental exposure to product, Product dose omission issue, Device defective, |
||||
GUSELKUMAB, |
||||
| 1279 | 24966723 |
US |
72 | 2 |
Incorrect dose administered by device, Device difficult to use, Wrong technique in product usage process, Product communication issue, Injury associated with device, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 1280 | 24967231 |
US |
1 | |
Accidental exposure to product, Device issue, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 1281 | 24957495 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1282 | 24957847 |
CA |
56 | 2 |
Needle issue, Pneumonia, Accidental exposure to product, Fatigue, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, CICLESONIDE, FLUTICASONE FUROATE, BUPROPION HYDROCHLORIDE, BUPROPION, LEVOTHYROXINE SODIUM, ALBUTEROL SULFATE, ALBUTEROL, ERGOCALCIFEROL, XYLOMETAZOLINE HYDROCHLORIDE, |
||||
| 1283 | 24957856 |
US |
71 | 1 |
Accidental exposure to product, Device difficult to use, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1284 | 24958066 |
US |
2 | |
Product dose omission issue, Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 1285 | 24958172 |
US |
58 | 1 |
Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, Wrong technique in product usage process, Injection site pain, |
||||
ETANERCEPT, ETANERCEPT, ETANERCEPT, |
||||
| 1286 | 24958213 |
US |
2 | |
Accidental exposure to product, No adverse event, |
||||
LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 1287 | 24958265 |
US |
64 | 2 |
Injection site mass, Therapeutic response shortened, Device difficult to use, Drug dose omission by device, Accidental exposure to product, Migraine, Injection site bruising, Injection site pain, Injection site discomfort, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 1288 | 24958330 |
US |
2 | |
Device physical property issue, Occupational exposure to product, Accidental exposure to product, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 1289 | 24958610 |
US |
64 | 2 |
Crohn^s disease, Device issue, Needle issue, Accidental exposure to product, Product dose omission issue, Off label use, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 1290 | 24958695 |
US |
||
Accidental exposure to product, Accidental exposure to product, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, |
||||
| 1291 | 24959082 |
US |
40 | 2 |
Accidental exposure to product, Device defective, |
||||
GOLIMUMAB, ETANERCEPT, ADALIMUMAB, ESCITALOPRAM, SPIRONOLACTONE, |
||||
| 1292 | 24959140 |
US |
69 | 2 |
Cellulitis, Pain, Swelling, Sciatica, Chest discomfort, Cough, Wheezing, Product dose omission issue, Accidental exposure to product, Wrong technique in product usage process, Product quality issue, Hypersensitivity, |
||||
OMALIZUMAB, OMALIZUMAB, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, GLIPIZIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, CARVEDILOL, GABAPENTIN, CYCLOBENZAPRINE, TORSEMIDE, ROSUVASTATIN, LOSARTAN, DAPAGLIFLOZIN, MONTELUKAST, SEMAGLUTIDE, INSULIN GLARGINE, BAYER ASPIRIN EXTRA STRENGTH, |
||||
| 1293 | 24960141 |
US |
12 | 2 |
Incorrect dose administered by device, Accidental exposure to product, Exposure via skin contact, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 1294 | 24961215 |
US |
91 | 2 |
Ocular discomfort, Ocular hyperaemia, Product use in unapproved indication, Product packaging quantity issue, Intentional product use issue, Product label issue, Product use complaint, Product delivery mechanism issue, Accidental exposure to product, Exposure via skin contact, Circumstance or information capable of leading to medication error, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, LIFITEGRAST, |
||||
| 1295 | 24961321 |
US |
2 | |
Device malfunction, Accidental exposure to product, Contusion, Off label use, |
||||
OMALIZUMAB, |
||||
| 1296 | 24961524 |
US |
13 | 2 |
Fear of injection, Incorrect dose administered by device, Accidental exposure to product, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 1297 | 24961548 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Product substitution issue, Device use error, Device leakage, |
||||
ADALIMUMAB-ADAZ, |
||||
| 1298 | 24962494 |
US |
21 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 1299 | 24962500 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1300 | 24962508 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28